ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1634

Body Mass Index and Disease Activity in Systemic Lupus Erythematosus- a Paradoxical Relationship?

George Stojan1, Wei Fu2 and Michelle Petri3, 1Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, 2Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, 3Medicine (Rheumatology), Division of Rheumatology, Johns Hopkins University School of Medicine, MD, USA, Baltimore, MD

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Disease Activity, Obesity and systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 6, 2017

Title: Systemic Lupus Erythematosus – Clinical Aspects and Treatment Poster II: Damage and Comorbidities

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:

Obesity is more common in patients with SLE compared to the general population. The prevalence of obesity among SLE patients is between 28 and 50 percent. Despite the high prevalence of obesity in this population, the effect of obesity on disease activity in SLE has not been studied. We hypothesized that the BMI at cohort entry was predictive of future disease activity and that changes in BMI during cohort follow up were associated with disease activity independent of corticosteroid treatment.

Methods:

2406 patients in a prospective SLE cohort had their weight assessed at each visit. Patients were categorized into five predetermined groups based on weight: low (BMI<20 kg/m2), normal weight (reference, BMI 20-24.9 kg/m2), overweight (25-29.9 kg/m2), obese (BMI 30-34.9 kg/m2), and severely obese (BMI>35 kg/m2). To calculate adjusted mean of SLEDAI over time, we only included patients attending the clinic at 3 month intervals for a minimum of 3 visits. 1896 patients were included in the analysis. 1763 (93.0%) were females. Majority (53.0%) were Caucasians, 39.0% African American. A within-person analysis was then performed to assess whether a person’s disease activity level changed if a person’s BMI changed.

Results:

Adjusted mean of SLEDAI over time did not differ between different BMI groups (table 1). SLEDAI significantly decreased by 0.03 with one unit increase in BMI (table 2). In Table 3, we calculated association between mean centered BMI (BMI – individual average BMI) and mean centered SLEDAI (SLEDAI – individual average SLEDAI) which showed a similar association.

Table 1. Adjusted Mean of SLEDAI Over Time by BMI at Entry Visit

BMI

N (%)

SLEDAI Mean (SD)

P value

Normal (Reference)

655(34.5)

2.7(2.4)

REF

Low

183(9.7)

2.9(2.2)

1

Overweight

531(28)

2.5(2.1)

1

Obese

290(15.3)

2.6(2.1)

1

Severely Obese

237(12.5)

2.5(2.1)

1

Table 2. Association of Disease activity with continuous BMI

Mean difference (95% CI)

P value

Adj. Mean difference (95%CI)*

P value

BMI

-0.03 (-0.04, 0.01)

<0.0001

-0.03(-0.04,-0.02)

<0.0001

* Adjust for age, race and prednisone at visit

Table 3. Association of mean centered SLEDAI with mean centered BMI

Mean difference (95% CI)

P value

Adj. Mean difference (95%CI)*

P value

Mean Centered BMI

-0.06(-0.07,-0.05)

<0.0001

-0.06(-0.07,-0.05)

<0.0001

* Adjust for age, race and prednisone at visit

Conclusion:

Body weight at cohort entry was not predictive of future disease activity. There was an inverse correlation between changes in body mass index and disease activity even after adjusting for prednisone use. This is the first evidence to our knowledge of an obesity paradox in systemic lupus.


Disclosure: G. Stojan, None; W. Fu, None; M. Petri, Anthera Inc, 5,GlaxoSmithKline, 5,EMD Serono, 5,Eli Lilly and Company, 5,Bristol Meyer Squibb, 5,Amgen, 5,United Rheumatology, 5,Global Academy, 5,Exagen, 2.

To cite this abstract in AMA style:

Stojan G, Fu W, Petri M. Body Mass Index and Disease Activity in Systemic Lupus Erythematosus- a Paradoxical Relationship? [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/body-mass-index-and-disease-activity-in-systemic-lupus-erythematosus-a-paradoxical-relationship/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/body-mass-index-and-disease-activity-in-systemic-lupus-erythematosus-a-paradoxical-relationship/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology